Skin-Derived Macrophages from Leishmania major-Susceptible Mice Exhibit Interleukin-12- and Interferon-γ-Independent Nitric Oxide Production and Parasite Killing After Treatment with Immunostimulatory DNA  by von Stebut, Esther et al.
Skin-Derived Macrophages from Leishmania major-Susceptible
Mice Exhibit Interleukin-12- and Interferon-g-Independent
Nitric Oxide Production and Parasite Killing After Treatment
with Immunostimulatory DNA
Esther von Stebut,*² Yasmine Belkaid,³ Bai Nguyen,² Mark Wilson,² David L. Sacks,³ and Mark C. Udey²
*Department of Dermatology, Johannes Gutenberg-University, Mainz, Germany; ³Laboratory of Parasitic Diseases, NIAID, National Institutes of
Health, Bethesda, U.S.A.; ²Dermatology Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, U.S.A.
Co-administration of CpG-containing immunosti-
mulatory oligodeoxynucleotides and parasite antigen
protects susceptible BALB/c mice from otherwise
progressive infection with Leishmania major. Although
the protective effect of CpG-containing immunosti-
mulatory oligodeoxynucleotides is clearly dependent
on endogenous interleukin-12 and interferon-g pro-
duction, the source of these Th1-promoting cyto-
kines in infected mice is unknown. In contrast to
macrophages from Leishmania-resistant C57BL/6
mice, macrophages from susceptible BALB/c mice
are hyporesponsive to stimulation with lipopolysac-
charide and interferon-g. While studying interactions
of various antigen-presenting cells with Leishmania,
we found that BALB/c in¯ammatory skin macro-
phages, whether Leishmania-infected or uninfected,
produced large amounts of interleukin-12 when trea-
ted with CpG-containing immunostimulatory oligo-
deoxynucleotides. Like lipopolysaccharide, CpG-
containing immunostimulatory oligodeoxynucleo-
tides induced production of interferon-g and release
of nitric oxide by skin macrophages. Studies using
skin macrophages from interleukin-12- and inter-
feron-g-de®cient BALB/c mice demonstrated that
nitric oxide release was not dependent on interleu-
kin-12 and interferon-g production. Approximately
44% and 27% of intracellular Leishmania major amas-
tigotes were killed by infected skin macrophages
within 72 h upon stimulation with CpG-containing
immunostimulatory oligodeoxynucleotides and lipo-
polysaccharide, respectively. Parasite killing by
macrophages was independent of endogenous inter-
feron-g production, but was strongly enhanced by
exogenous interferon-g. Parasite elimination was
dependent on the induction of nitric oxide, however.
In vivo, injection of CpG-containing immunostimula-
tory oligodeoxynucleotides into lesional skin reduced
the parasite burden »50-fold within the ®rst 5 d of
infection prior to full generation of a Th response.
These results suggest that skin macrophages, consti-
tuting the principal reservoir of parasites in infected
susceptible mice, produce Th1-promoting cytokines
in response to CpG-containing immunostimulatory
oligodeoxynucleotides. In addition, CpG-containing
immunostimulatory oligodeoxynucleotides may also
act locally on skin macrophages to facilitate
Leishmania clearance by inducing nitric oxide pro-
duction. Key words: CpG motif/cytokines/Leishmania/
monocytes/macrophages/nitric oxide. J Invest Dermatol
119:621±628, 2002
M
urine Leishmania major infection provides an
excellent experimental system in which to study
factors that regulate Th development and repre-
sents a useful model of an important human
disease (cutaneous leishmaniasis). Resistant (e.g.,
C57BL/6) mice mount Th1-predominant immune responses and
control parasite growth, whereas susceptible BALB/c mice exhibit
Th2 immunity and succumb to progressive disease (Reiner and
Locksley, 1995; Locksley et al, 1999). Manipulations that block
production of Th1-promoting cytokines like interleukin-12 (IL-
12) or interferon-g (IFNg), or that enhance development of Th2
responses, convert resistant animals into susceptible ones.
Conversely, treatment of BALB/c mice with IL-12 or anti-IL-4
prevents disease, and targeted mutation of the genes that encode IL-
4 or the a chain of the IL-4 receptor confers partial protection
(Mohrs et al, 1999).
Murine skin macrophages (MF) rapidly ingest L. major
promastigotes after dermal inoculation by sand ¯ies. Initially, it
was suggested that skin MF might be the principal source of Th1-
promoting IL-12 early in infection (reviewed in Scott, 1996).
Subsequently, it was determined that infected skin MF did not
release IL-12 and, in addition, parasitized MF were hyporesponsive
to in¯ammatory stimuli (Carrera et al, 1996). Prior results from our
laboratory together with several other studies implicate dendritic
cells (DC) rather than MF as early, and important, sources of IL-12
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production in parasitic infections (Reis e Sousa et al, 1997; Gorak et
al, 1998; von Stebut et al, 1998). Studies on interactions of
Leishmania with skin DC from susceptible BALB/c and resistant
C57BL/6 mice subsequently revealed that BALB/c DC ingested
organisms, upregulated major histocompatibility complex (MHC)
and costimulatory molecules, and produced as much, or more, IL-
12 than C57BL/6 DC (von Stebut et al, 2000). Other accessory
cells (particularly skin MF) do exhibit strain-dependent differences
in response to several in¯ammatory stimuli, however (Liew et al,
1991; Alleva et al, 1998; Mills et al, 2000).
Escherichia coli lipopolysaccharide (LPS) is a prototypic agonist of
the innate immune system and strain-dependent differences in LPS
responsiveness have been described previously (Alleva et al, 1998;
Mills et al, 2000). Studies with various MF populations indicated
that, with regard to IL-12 production, BALB/c-derived cells are
generally hyporesponsive to LPS (or LPS and IFNg) compared with
analogous populations from C57BL/6 mice (Belkaid et al, 1998;
von Stebut and Udey, unpublished observations). We examined
immunostimulatory DNA as an alternative stimulus of innate
immune responses because it has unique immunomodulatory
properties and immunostimulatory oligodeoxynucleotides (ODN)
have therapeutic ef®cacy in the prevention and treatment of
experimental murine cutaneous leishmaniasis.
The immunity-enhancing activities of immunostimulatory DNA
result from unmethylated CpG dinucleotides that are frequent in
bacterial DNA and that activate natural killer cells, B cells, MF,
DC, and T cells (Ballas et al, 1996; Stacey et al, 1996; Yi et al, 1996;
Sparwasser et al, 1998; Jakob et al, 1999; Bendigs et al, 1999). CpG
dinucleotide sequences in appropriate motifs (CpG-ODN) com-
prise the adjuvant component of plasmid DNA vaccines, and are
largely responsible for the strong Th1 bias of immune responses that
are initiated via this approach (Carson and Raz, 1997; Klinman et
al, 1999). The ability of CpG-ODN to in¯uence the outcome of
immune responses is illustrated in studies in which CpG-ODN
promote development of Th1-predominant immunity to model
protein antigens in normally Th2-biased BALB/c mice (Kline et al,
1998; Zimmermann et al, 1998; Walker et al, 1999). Results of
experiments in which CpG-ODN switched established Th2
responses that cause bronchospasm in mice to Th1 responses
(Kline et al, 1998), and those in which otherwise lethal bacterial and
parasitic infections of mice were aborted (Zimmermann et al, 1998;
Walker et al, 1999), suggest that CpG-ODN may have clinical
utility.
The ability of CpG-ODN to convert ineffective anti-Leishmania
vaccines into vaccines with ef®cacy, and to abort murine cutaneous
leishmaniasis, has been documented in several laboratories, includ-
ing ours (Zimmermann et al, 1998; Stacey and Blackwell, 1999;
Walker et al, 1999). The anti-Leishmania activity of CpG-ODN is
dependent on endogenous IL-12 and IFNg production (Walker et
al, 1999). Because previous studies indicated that CpG-ODN
activated skin DC in vivo as well as in vitro (Sparwasser et al, 1998;
Jakob et al, 1999), we inferred that DC were an important source of
IL-12 in CpG-ODN treated, L. major-infected BALB/c mice.
Results described herein demonstrate that BALB/c skin MF also
produce bioactive IL-12, IFNg, and nitric oxide (NO) in direct
response to CpG-ODN alone. These results suggest that, although
the anti-Leishmania effects of CpG-ODN in susceptible mice are
mediated through a variety of immune and in¯ammatory cells (DC,
T cells, and MF), direct actions of CpG-ODN on skin MF may be
important determinants of CpG-ODN ef®cacy. We suggest that
CpG-ODN-mediated protection against Leishmania infection in
BALB/c mice is mediated, at least in part, via induction of Th1-
promoting cytokines as well as enhanced NO-dependent killing of
parasites by lesional skin MF.
MATERIALS AND METHODS
Animals Six- to 8-wk-old female BALB/CAnNCr were purchased
from the National Cancer Institute Animal Production Program
(Frederick, MD). BALB/c with targeted mutations of genes encoding
IL-12 p40 (Magram et al, 1996) and IFNg (BALB/c-IfngtmlTs) (Dalton et
al, 1993) were kindly provided by Drs. Brian Kelsall (NIAID, NIH) and
Alan Sher (NIAID, NIH), respectively. All animals were housed and
used in experiments in accordance with institutional guidelines.
Cells In¯ammatory murine skin-derived MF were elicited by
subcutaneous injection of sterile polyacrylamide beads (Fauve et al, 1983;
Belkaid et al, 1998; von Stebut et al, 1998). In®ltrates were harvested
after 3±4 d and cells were separated from beads by ®ltering through
70 mm nylon mesh. MF were resuspended in Dulbecco's modi®ed
Eagle's medium (Gibco BRL, Grand Island, NY) supplemented with
10% fetal bovine serum (Bio¯uids, Rockville, MD), and enriched to near
homogeneity (based on reactivity with monoclonal antibody F4/80 and
anti-CD11b) using a 4 h plastic adherence step followed by vigorous
washing. Adherent cells were released by incubation in 2 mg per ml
glucose in phosphate-buffered saline on ice, counted, and replated in
medium at the indicated densities before ¯uorescence-activated cell sorter
analysis or treatment with agonists.
Antibodies and ¯ow cytometry Anti-CD3e (145-2C11), anti-CD4
(GK1.5), anti-CD8 (53-6.7), anti-CD16/CD32 (2.4G2), anti-I-Ab,d/I-Ed
(2G9), anti-I-Ad (AMS-32.1), anti-CD11b (M1/70), anti-CD40 (3/23),
anti-CD54 (3E2), anti-CD80 (1G10), anti-CD86 (GL1), anti-NK1.1
(PK136), and anti-Pan natural killer cells (DX5) were purchased as
biotin- or phycoerythrin-modi®ed monoclonal antibodies (PharMingen,
Burlingame, CA). Biotin-conjugated anti-F4/80 was obtained from
Serotec (Raleigh, NC) and phycoerythrin-streptavidin was from Tago
(Burlingame, CA). Cells were stained for surface Ag expression and
analyzed using a FACScan ¯ow cytometer equipped with Cell Quest
software (Becton Dickinson, Mountain View, CA) as previously
described (von Stebut et al, 1998). Propidium-iodide-permeable cells
were excluded from analyses. Neutralizing anti-IL-12 (C17.8) was
prepared as described previously (Walker et al, 1999) and anti-IFNg
(R4±6A2) monoclonal antibody was purchased from PharMingen.
DNA preparations, LPS, and cytokines ODN with nuclease-
resistant phosphorothioate backbones were synthesized by Oligos Etc.
(Wilsonville, OR). The ODNs used were selected because of their
activity in prior studies (Jakob et al, 1999; Walker et al, 1999). Sequences
of the 20-mer CpG-ODN and the corresponding composition-matched
control ODN used were as follows: CpG-ODN 1826, 5¢-
TCCATGACGTTCCTGACGTT-3¢; and ODN 1911, 5¢-
TCCAGGACTTTCCTCAGGTT-3¢. Sodium salts of ODN were stored
at ±20°C and diluted in phosphate-buffered saline before use. LPS
contamination in ODN preparations was undetectable with the Limulus
amebocyte lysate (LAL) assay (Bio-Wittaker, Walkerville, MD). E. coli
K235-derived LPS was a kind gift from Dr. Stefanie Vogel (Uniformed
Services, University of the Health Sciences, Bethesda, MD).
Recombinant murine IFNg was purchased from PeproTech (Rocky Hill,
NJ). For stimulation, isolated cells were subcultured in their basal
medium at 2 3 105 per ml or 1 3 106 per ml as indicated in the ®gure
legends; LPS (100 ng per ml), IFNg (1000 U per ml), and ODN (0.1±
100 mg per ml) were added as indicated.
Quantitation of cytokine and NO production Cytokine release into
18 or 72 h cell supernatants was measured using enzyme-linked
immunosorbent assay (ELISA) kits for murine IL-12 p40, IL-12 p70, and
tumor necrosis factor a (TNFa) (PharMingen, San Diego, CA). IFNg
ELISA kits were purchased from R&D Systems (Minneapolis, MN).
Seventy-two hour supernatants were assayed for the presence of nitrite (a
stable derivative of NO) as described previously (Stuehr and Nathan,
1989). Brie¯y, supernatants were incubated with equal volumes of Griess
reagent, and nitrite content was quantitated spectrophotometrically.
Sodium nitrite (Sigma Chemical, St. Louis, MO) was used to standardize
the assay.
Assessment of leishmanicidal activity in vitro and in vivo Metacyclic
promatigotes of L. major clone VI (MHOM/IL/80/Friedlin) were
prepared as described previously (Belkaid et al, 1998). Isolated parasites
were opsonized with 5% normal mouse serum and washed prior to
infection. Levels of LPS in parasite stock preparations were below the
limit of detection (< 1 pg per ml) in the LAL assay. Skin MF were
plated at 3 3 105 per well in Permanox microchamber slides (Nalgene,
Naperville, IL). Parasites were added (®ve organisms per cell) for 4 h.
Subsequently, free parasites were washed away and cells were treated in
basal medium with agonists as indicated. In some experiments, NO
synthase inhibitory NG.-monomethyl-L-arginine (L-NMMA) or inactive
NG.-monomethyl-D-arginine (D-NMMA) (Alexis Biochemicals, San
Diego, CA) was added at 250 mM together with agonists. Cells were
stained with DiffQuick for assessment of intracellular parasites. A
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minimum of 200 cells per condition were counted by an investigator
blinded to the experimental design using a light microscope. The
number of intracellular amastigotes per 100 cells was quantitated and the
change compared to untreated control MF (= 100%) was calculated.
For in vivo experiments, 2 3 105 metacyclic promastigotes were
injected into ventral sides of the ears in volumes of 10 ml (day 0). On
day 1, CpG-ODN or ODN 1911 (10 mg per 10 ml) were injected
locally. After 5 d, ears were harvested and the parasite load was
determined as described previously (Belkaid et al, 2000).
To assess the IL-12-producing capacity of L. major-infected skin MF
in vivo, skin MF were infected in situ by local injection of 5 3 106
metacyclic promastigotes 3 d after initiation of polyacrylamide granulo-
mas. After 2 h, CpG-ODN 1826 or ODN 1911 were injected locally
(10 mg per 50 ml). Cells were harvested after an additional 2 h, enriched
by plastic adherence as described above, and replated at 1 3 106 cells per
ml in Dulbecco's modi®ed Eagle's medium/5% fetal bovine serum. A
fraction of cells was cytospun and stained with DiffQuick for determin-
ation of infection rates by light microscopy. Supernatants were harvested
after 18 h and IL-12 p40 was determined by ELISA.
Statistics Statistical analysis was performed using the unpaired
Student's t test.
RESULTS
Induction of IL-12 release from murine skin-derived MF by
CpG-ODN Previous studies demonstrated that CpG-ODN that
exhibit anti-Leishmania activity stimulate skin DC in vitro and in vivo
(Zimmermann et al, 1998; Jakob et al, 1999; Walker et al, 1999).
One consequence of activation is IL-12 production, and DC-
derived IL-12 may facilitate the development of protective Th1-
predominant immunity. We have reported previously that skin DC
from both Leishmania-susceptible (BALB/c) as well as resistant
(C57BL/6) mice are similarly responsive to L. major and
in¯ammatory stimuli (von Stebut et al, 1998; 2000). In particular,
skin DC from BALB/c and C57BL/6 mice were comparable with
respect to their ability to produce bioactive IL-12 in response to L.
major amastigotes, CpG-ODN, LPS, or LPS/IFNg. In this study we
examined a variety of accessory cells isolated or propagated from
Leishmania-resistant and susceptible mice. Although BALB/c
peritoneal exudate and bone marrow MF as well as bone-
marrow-derived DC all released 2±6-fold less IL-12 than C57BL/6
cells in response to LPS 6 IFNg (data not shown), BALB/c skin
MF were most dramatically de®cient, producing »20-fold less IL-
12 p40 (Table I). This result is consistent with ¯ow cytometry data
reported previously (Belkaid et al, 1998). Strain-dependent
differences in the release of other cytokines (TNFa, IL-6, IL-10,
IL-4) by skin MF were not detected (data not shown).
Extension of these studies to infection with Leishmania revealed
that, as expected, skin MF elicited in BALB/c and C57BL/6 mice
by subcutaneous injection of sterile polyacrylamide beads failed to
produce IL-12 in response to Leishmania infection (Table I, and
Belkaid et al, 1998). Prior infection of C57BL/6 skin MF with L.
Table I. CpG-ODN-induced release of IL-12 from BALB/c skin MF is not inhibited in L. major-infected cellsa
BALB/c C57BL/6
Uninfected L. major Uninfected L. major
IL-12 p40
Control 11 6 9 7 6 7 6 6 6 6 6 6
LPS/IFNg 194 6 79* 283 6 193 3934 6 1,403* 2300 6 1,284*
CpG-ODN 1826 1853 6 1,309* 1920 6 1,634* 523 6 260 401 6 264
ODN 1911 14 6 14 14 6 14 14 6 14 n.d.
IL-12 p70
Control 58 6 44 69 6 69 22 6 15 112 6 82
LPS/IFNg 118 6 46 181 6 111 462 6 114* 280 6 173
CpG-ODN 1826 390 6 174* 455 6 339 59 6 32 15 6 15
ODN 1911 72 6 72 72 6 72 130 6 103 n.d.
aSkin MF(n = 5) were incubated with L. major promastigotes (®ve organisms per cell). Four hours later, LPS (100 ng per ml), IFNg (1000 U per ml), CpG-ODN 1826
(10 mg per ml), or control ODN 1911 (10 mg per ml) were added as indicated. Cytokine levels in 18 h supernatants were determined by ELISA. Values represent pg per
ml of cytokine produced by 2 3105 cells per ml in 18 h (mean 6SEM).
*p > 0.05 compared with untreated control. n.d., not done.
Figure 1. CpG-ODN are strong inducers of IL-12 p70 in BALB/c
skin-derived MF. Polyacrylamide-bead-elicited skin-derived BALB/c
MF were incubated with various concentrations of CpG-ODN 1826 or
control ODN 1911 (0.1±100 mg per 2 3 105 cells per ml) with or
without IFNg (1000 U per ml) as indicated. Cytokine levels were
determined in 18 h supernatants by ELISA. Data from one of two
experiments with similar results are shown.
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major also blunted their response to subsequent challenge with high
concentrations of LPS and IFNg with regard to IL-12 production
(Carrera et al, 1996). C57BL/6 skin MF treated with CpG-motif-
containing ODN 1826 released only small amounts of IL-12 p40
compared to LPS/IFNg stimulated cells. In contrast, treatment of
BALB/c skin MF with CpG-ODN 1826 resulted in the release of
considerable IL-12 p40 and p70 relative to cells treated with non-
CpG-containing ODN 1911 (Table I, Fig 3A later) or LPS plus
IFNg. Interestingly, prior infection of BALB/c skin MF with L.
major did not inhibit cytokine production in response to CpG-
ODN 1826 (Table I). Although additional stimulation of BALB/c
skin MF with IFNg together with CpG-ODN 1826 had no effect
on IL-12 p40 release, combined treatment resulted in production of
high levels of IL-12 p70 (Fig 1). To determine the activating
potential of CpG-ODN 1826, we analyzed the release of pro-
in¯ammatory TNFa from BALB/c skin MF treated with either
CpG-ODN 1826 (6 IFNg) or IFNg alone. High concentration of
CpG-ODN (100 mg per ml) appeared to be supra-optimal. Using
trypan blue exclusion, however, no apparent toxicity of CpG-
ODN for skin MF was observed over the period of 72 h compared
to untreated medium controls. Interestingly, as the combination of
CpG-ODN together with IFNg led to increased IL-12 p70 release
whereas CpG-ODN alone did not to the same extent, we speculate
that IL-12 p35 might be upregulated upon additional stimulation
with IFNg.
CpG-ODN, unlike LPS, appeared to be potent inducers of IL-
12 release by infected MF from Leishmania-susceptible mice. As
this might be particularly relevant for therapeutic purposes, we
subsequently focused on studying the effects of CpG-ODN on
BALB/c skin MF.
Effects of CpG-ODN on other parameters of BALB/c skin
MF activation Although CpG-ODN induced release of
signi®cant amounts of IL-12 from BALB/c skin MF, only
modest changes in cell surface antigen expression were observed
(Fig 2). CpG-ODN as well as LPS induced a 3±4-fold increase in
CD54 and 2.5±4-fold increase in CD40 expression after 48 h. Cell
surface alterations were even less marked when studying other
surface markers (e.g., CD80, CD86) or at earlier time points (data
not shown). In all cases, the changes in cell surface marker
expression caused by CpG-ODN were less dramatic than those
induced by LPS/IFNg. Only small amounts of MHC class II were
detected on BALB/c skin MF independent of the antibody used
for detection. Additionally, only minimal upregulation of MHC
class II antigens was detected after stimulation with LPS/IFNg or
CpG-ODN. This is consistent with previous observations and
re¯ects the relative immaturity of MF elicited in polyacrylamide-
bead-injected skin compared to MF from other sources (bone-
marrow-derived MF, thioglycollate-elicited MF) (Belkaid et al,
1998; von Stebut et al, 1998). Skin MF, however, as well as other
MF preparations were uniformly positive for lineage markers such
as F4/80 (Fig 2) and CD11b (data not shown).
Induction of NO and IFNg production in BALB/c skin MF
by CpG-ODN and LPS Skin-MF-derived NO and IFNg
production may augment innate responses and might play
important roles in the initiation of protective immune responses
in murine cutaneous leishmaniasis (Zimmermann et al, 1998;
Walker et al, 1999). Exposure of BALB/c skin MF to CpG-ODN
alone resulted in the production of NO (measured as nitrite
accumulation) in 72 h supernatants that was comparable to cells
stimulated with LPS/IFNg or CpG-ODN/IFNg (Fig 3B). In
contrast, addition of the composition-matched control ODN 1911
or Leishmania parasites (parasite to cell ratio 3:1) was without effect
(data not shown). Surprisingly, although LPS induced only modest
upregulation of IL-12 release and surface antigen expression, NO
production by LPS-treated BALB/c skin MF was comparable to
that induced by LPS/IFNg or CpG-ODN 1826 6 IFNg.
Induction of NO in MF after IFNg exposure constitutes the
major effector mechanism that facilitates Th1-cell-dependent
killing of Leishmania parasites (Reiner and Locksley, 1995). To
determine if production of NO induced by CpG-ODN or LPS
stimulation alone was dependent on endogenous IFNg production
from skin MF (previously described for other MF populations:
Gessani and Belardelli, 1998; Munder et al, 1998), we assayed 72 h
supernatants of CpG-ODN- or LPS-treated skin MF for the
presence of IFNg. As shown in Fig 3, BALB/c skin MF released
IFNg after treatment with immunostimulatory DNA as well as LPS.
To determine if production of IFNg and NO by BALB/c skin
MF was dependent on the production of IL-12 and/or IFNg
(Munder et al, 1998) (Fig 3A), skin MF prepared from BALB/c
IL-12 p40 or IFNg knockout mice were stimulated with LPS or
CpG-ODN (6 IFNg) and mediator release was quanti®ed
(Fig 3D). Surprisingly, NO production by cytokine-de®cient
MF compared to wild-type MF was not reduced after stimulation
with CpG-ODN or LPS, suggesting that neither CpG-ODN- nor
LPS-induced NO production by skin MF was dependent on IL-12
or IFNg synthesis. These results are in agreement with the results of
experiments carried out with wild-type BALB/c skin MF and
neutralizing anti-IL-12 and/or anti-IFNg antibodies (data not
shown).
CpG-ODN induces parasite killing via NO induction in
BALB/c skin MF We next wanted to determine if NO
induction by CpG-ODN (or LPS) was suf®cient to mediate
parasite killing in Leishmania-infected cells. Skin MF of wild-type
BALB/c mice were infected with metacyclic promastigotes of L.
major in vitro and stimulated with CpG-ODN or LPS in the
presence or absence of IFNg (Fig 4). The number of intracellular
amastigotes was determined after 72 h. The infection rate of
untreated control skin MF in these experiments was 32 6 6% and
the number of amastigotes per 100 cells was 70 6 20 (n = 11).
Figure 2. Activation of skin MF with CpG-ODN induces
upregulation of costimulatory molecules. Skin-derived BALB/c
MF were incubated with LPS (100 ng per ml), IFNg (1000 U per ml),
or oligonucleotides (10 mg per ml) for 48 h as indicated. Plastic adherent
skin MF were released from culture dishes and serially incubated with
biotin-rat monoclonal antibody and phycoerythrin-streptavidin, and
analytical ¯ow cytometry was performed. Solid line, isotype staining;
shaded area, antibody of interest. Only propidium-iodine-impermeable
cells were studied. Numbers in upper right corner represent mean
¯uorescence intensity. Numbers underneath bar indicate percentage
positive cells. Data from one of three similar experiments are shown.
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Upon treatment with either CpG-ODN or LPS, skin MF
eliminated 44 6 7% and 27 6 6% of intracellular amastigotes,
respectively, whereas control ODN-treated skin MF did not kill
parasites. As expected, addition of exogenous IFNg to the cultures
(Fig 4A) strongly increased parasite killing up to 72 6 5% (CpG-
ODN/IFNg) and 75 6 5% (LPS/IFNg). We observed no apparent
toxicity of CpG-ODN or LPS treatment over the time period
studied (data not shown). As suggested from the results shown in
Fig 3(D), elimination of parasites from infected cells was no
different in IFNg-de®cient skin MF, but was strongly inhibited
upon addition of NO-inhibiting L-NMMA (but not inactive D-
NMMA) to the cultures (Fig 4B). These data demonstrate that
CpG-ODN-induced killing of L. major parasites by skin MF is
dependent on the production of NO and can be enhanced by
exogenous IFNg, but it is not dependent on endogenous IFNg
production.
Local administration of CpG-ODN facilitates parasite
killing independent of Th1 cells and induces release of IL-
12 from lesional MF To extend our in vitro ®ndings, we tested
whether CpG-ODN have the capability to induce parasite killing
locally at very early times after infection before full generation of
Th1 immunity is observed. Groups of ®ve BALB/c mice were
infected intradermally with 2 3 105 metacyclic promastigotes of L.
major, and 10 mg of CpG-ODN 1826 or composition-matched
ODN 1911 was injected locally 18 h later. Five days after infection,
ears were harvested and parasite load was determined in limiting
dilution assays. As shown in Fig 5(A), administration of CpG-
ODN reduced the number of lesional parasites »50-fold compared
to ODN 1911 suggesting that CpG-ODN might contribute
directly to early parasite elimination independent of IFNg-
producing Th1 cells.
CpG-ODN were also able to induce IL-12 production from skin
MF in vivo in the presence or absence of infection (Fig 5B).
BALB/c skin MF were infected in vivo by injection of metacyclic
promastigotes into polyacrylamide-gel-induced granulomas
(Belkaid et al, 1998). After 2 h, 10 mg CpG-ODN or ODN
1911 was injected locally, and after additional 2 h skin MF were
harvested and placed in medium for 18 h. The infection rates of
MF were determined on cytospins stained with DiffQuick. The
infection rates were 8.9 6 0.7% and 12.2 6 1.3% for CpG-ODN
and ODN 1911-treated MF (Belkaid et al, 1998), which is
comparable to the number of infected MF in lesional tissues
(Belkaid et al, 2000). Analysis of supernatants for IL-12 p40 content
revealed that only skin MF from CpG-ODN-injected granulomas
released signi®cant amounts of IL-12 (p < 0.002, Fig 5B). This
effect was independent of infections with L. major.
DISCUSSION
This study demonstrates that CpG-ODN with anti-Leishmania
activity in vivo are potent and direct agonists of IL-12, IFNg, and
NO release by BALB/c skin-derived MF. Our results reinforce the
notion that CpG-ODN can act on a variety of cells, including skin
MF and skin DC (Jakob et al, 1999), to produce a number of
Figure 3. Immunostimulatory DNA is a
potent agonist of IL-12, NO, and IFNg
production by skin MF from Leishmania-
susceptible BALB/c mice. Skin MF (2 3 105
per 200 ml) from wild-type BALB/c (n > 5), IL-
12-de®cient (n = 2), or IFNg-de®cient (n = 4)
BALB/c mice were incubated with LPS (100 ng
per ml), CpG-ODN 1826, or control ODN 1911
(10 mg per ml) with or without IFNg (1000 U
per ml) for 72 h as indicated. Nitrite
concentrations were measured using the Griess
reagent and cytokine levels were determined in
supernatants by ELISA. Statistical signi®cance
compared to control treatment was calculated
using Student's t test for unpaired samples
(*p < 0.05, ***p < 0.005).
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soluble factors that collectively abrogate disease in an animal model
of an important human disease.
In this study we con®rmed that accessory cells from BALB/c
mice, particularly skin MF, are hyporesponsive to in¯ammatory
mediators such as LPS compared with their C57BL/6-derived
counterparts with regard to the production of Th1-promoting IL-
12 (Oswald et al, 1992; Alleva et al, 1998; Mills et al, 2000). To the
extent that these skin-derived MF resemble the in¯ammatory MF
population in Leishmania lesions, our ®ndings may be particularly
relevant. Strain differences in MF may contribute to the increased
susceptibility of BALB/c mice to L. major infection. Whether the
strain differences that we and others observed are intrinsic to these
leukocytes, or re¯ect strain-dependent variations in cutaneous
microenvironments or receptor expression (TLR4 for LPS versus
TLR9 for CpG signaling), remains to be determined. Our
observations that BALB/c skin MF were strikingly more respon-
sive to LPS and CpG-motif containing ODN relative to MF from
resistant C57BL/6 mice when IFNg and NO release were
quantitated (data not shown and Zhu et al, 2001), however, and
that other BALB/c MF populations are also LPS hyporesponsive
with regard to IL-12 production (compare also Alleva et al, 1998;
Mills et al, 2000), argue that these differences do not simply re¯ect
alterations in MF activation stage or the degree of maturation
(SunderkoÈtter et al, 1993).
Our data demonstrate that CpG-ODN alone induce a variety of
soluble mediators such as IL-12, TNFa, IFNg, and NO in BALB/c
skin MF, and may explain some of the immunomodulatory effects
seen with CpG-ODN treatment in cutaneous leishmaniasis. Skin
MF are the ®rst cells that are parasitized after dermal L. major
inoculation, and they constitute the principal parasite reservoir in
cutaneous leishmaniasis. Initial stages of cutaneous L. major are
nonin¯ammatory, or perhaps even anti-in¯ammatory (Carrera et al,
1996), allowing expansion of parasites in early lesions. CpG-ODN
are potent stimulators of BALB/c skin MF in vitro as well as in vivo,
even if cells are infected with L. major. Induction of skin MF IL-12
and IFNg production may facilitate the development of
Th1-predominant immunity that is observed in CpG-ODN-
treated Leishmania-infected mice. The direct action of CpG-ODN
on skin MF that results in IFNg and NO synthesis may also
contribute to early parasite elimination (MacMicking et al, 1997;
Gessani and Belardelli, 1998) by reducing the dose of antigen and
facilitating preferential Th1 education (Nabors et al, 1995).
The ability of CpG-ODN to induce signi®cant NO release from
skin MF in the absence of IL-12 or IFNg is also of interest. Several
groups have reported that exogenous IFNg was required for
immunostimulatory DNA-induced NO production by RAW
264.7 cells and MF propagated from CD1 mouse bone marrow
(Sweet et al, 1998). Others detected release of nitrite after priming
with IFNg and subsequent stimulation with CpG motifs (Ohashi et
al, 2000; Sester et al, 2000; Shoda et al, 2001). Recently, Gao and
coworkers noted that immunostimulatory DNA did not induce
NO release by RAW 264.7 cells in the absence of LPS, and that
synergy between LPS and bacterial DNA was IFNg independent in
this system (Gao et al, 1999). Puddu et al (1997) previously
demonstrated that resident murine peritoneal MF produced IFNg
in response to IL-12 and IL-18 whereas RAW 264.7 cells did not.
The results that we obtained with skin MF are not entirely
concordant with these studies. The discrepancies between results
reported previously and the data presented here may re¯ect the
varying sources (and states of activation) of the MF studied. In any
case, the data shown in this study suggest that local administration
of CpG-ODN might lead to the release of both IFNg and NO
from skin MF.
TNFa participates in the induction of NO production and MF
activation leading to the elimination of intracellular pathogens
(Green et al, 1990; Taylor and Murray, 1997; JuÈttner et al, 1998;
Wilhelm et al, 2001), although its leishmanicidal capacity is still
controversial as mice de®cient for TNF-R are able to control
parasite replication in vivo (Nashleanas et al, 1998). In this study we
observed that skin MF release large amounts of TNFa in response
to CpG-ODN 1826. Thus, CpG-ODN-induced TNFa produc-
tion not only might contribute to the recruitment of in¯ammatory
cells to the site of infection (Murray et al, 2000), but also may
facilitate NO-dependent parasite elimination by local resident MF.
NO is the principal effector molecule for MF-mediated cytotoxi-
city of intracellular Leishmania amastigotes (Green et al, 1994;
Murray and Nathan, 1999). Although IFNg regulated NO
Figure 4. CpG-motif-containing DNA induces leishmanicidal
activity in skin MF from BALB/c mice that is dependent on NO
but independent of IFNg induction. Skin MF (2 3 105 per 200 ml
per well) from wild-type BALB/c or BALB/c IFNg knockout mice
were infected with metacyclic L. major promastigotes (parasite to cell
ratio 5:1) for 4 h. Free parasites were removed and cells were incubated
with LPS (100 ng per ml), CpG-ODN 1826, or control ODN 1911
(10 mg per ml) with or without IFNg (1000 U per ml) as indicated. L-
NMMA and inactive D-NMMA were added at 250 mM. After 72 h,
slides were ®xed and stained with DiffQuick. Intracellular amastigotes
were counted in a minimum of 200 cells per condition; the mean
number of amastigotes per 100 cells was calculated as percentage of
untreated control. Infection rates of untreated controls were 32 6 6%
(BALB/c, n = 11), 24 6 13% (IFNg knockout, n = 3), 29 6 9% (L-
NMMA, n = 4), and 34 6 11% (D-NMMA, n = 4). Statistical
differences compared to control treatment were calculated by Student's t
test (*p < 0.05, ***p < 0.005).
Figure 5. CpG-ODN induce local parasite killing in vivo and
induce release of IL-12 from lesional MF. (A) Groups of ®ve
BALB/c mice were infected on day 0 by injection of 2 3 105
metacyclic L. major into ear skin. On day 1, 10 mg of CpG-ODN or
control ODN 1911 were injected locally. On day 5, parasite content was
determined by limiting dilution assay. Dots represent number of parasites
in ear skin of a single animal; bars show the arithmetic mean of all mice
per group. (B) Skin MF from BALB/c mice were infected in vivo with
metacyclic L. major promastigotes and stimulated in vivo 2 h later by local
injection of CpG-ODN 1826 or control ODN 1911 (10 mg per 50 ml)
as indicated. After an additional 2 h, cells were harvested and were
plated at 1 3 106 per ml medium, and supernatants were assayed for IL-
12 p40 production by ELISA (ng per ml per 18 h). Statistical differences
between groups were calculated by Student's t test (***p < 0.005).
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production, IFNg was not required for parasite killing in our
studies. Therefore, IL-12- and IFNg-independent induction of NO
by CpG-ODN in BALB/c skin MF may contribute to the local
elimination of Leishmania parasites in the skin.
CpG-ODN hold considerable promise as adjuvants that may be
useful in vaccination protocols against tumors and infectious agents,
and/or as immunomodulators that may be useful in the treatment
of autoimmune or allergic diseases. Current treatment of
leishmaniasis is expensive and toxic, and an ef®cient vaccine has
not been described. Thus, an inexpensive CpG-ODN-based
therapy might be of value. In this study we demonstrated that
CpG-ODN with activity in vivo may have important effects on
both local in¯ammatory and systemic immune responses. In murine
cutaneous leishmaniasis, CpG-ODN might contribute to ef®cient
development of protective immunity by reducing the initial parasite
burden (by induction of NO production in local skin MF) and also
by allowing for the development of Th1-predominant immune
responses via induction of IL-12 from local skin MF and DC.
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